Timothy Guzi

While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for EGFR mutant (L858R and ex19del) driven non-small-cell lung cancer (NSCLC), most patients will eventually develop resistance to TKIs…

Avapritinib and pralsetinib are FDA approved kinase inhibitors developed by Blueprint Medicines that target diseases driven by activating mutations in KIT and RET, respectively. The discovery-stage synthetic optimization of each compound will be described, highlighting significant problem-solving…

MOMA-341 is a chemically distinct, potent and selective clinical stage inhibitor of WRN that acts through covalent ligation. In tumors with high DNA microsatellite instability (MSI-H), WRN is required for survival…